Modalis Therapeutics Corporation
JPX: 4883.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Haruhiko Morita
- Employees
- 14
- Headquarters
- Tokyo, Japan
- IPO year
- 2020
- Market cap
- ¥5.9B
- Website
- https://modalistx.com
Loading 4883…
Loading profile data…Frequently asked questions about 4883
What does Modalis Therapeutics Corporation (4883.T) do?
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The compan...
Where does 4883.T trade?
Modalis Therapeutics Corporation (4883.T) trades on the Tokyo Stock Exchange.
What sector is 4883.T in?
Modalis Therapeutics Corporation (4883.T) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Modalis Therapeutics Corporation?
Haruhiko Morita is the chief executive officer of Modalis Therapeutics Corporation (4883.T).
Where is Modalis Therapeutics Corporation headquartered?
Modalis Therapeutics Corporation is headquartered in Japan.
Does 4883.T pay a dividend?
Modalis Therapeutics Corporation (4883.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4883.T go public?
Modalis Therapeutics Corporation (4883.T) completed its initial public offering in 2020.